Art. -Nr.: HY-12600

AZD5582

Name: AZD5582
Brand: MedChemExpress
SKU: HY-12600
Price: 90.00 USD
Availability: InStock
Rating: 5 (16 reviews)

16 Cited Publications

Kundenbewertung

Based on 16 publication(s) in Google Scholar

AZD5582 is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC₅₀s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.61%
CAS. Nr.: 1258392-53-8
Formel: C₅₈H₇₈N₈O₈
Molecular Weight:1015.29

Speicherung:

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

AZD5582 Chemical Structure

CAS. Nr.: 1258392-53-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (16)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

cIAP1

15 nM (IC₅₀)

cIAP2

21 nM (IC₅₀)

XIAP

15 nM (IC₅₀)

Alle IAP Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
MDA-MB-231	EC₅₀	0.1 nM Compound: 14, AZD5582	Binding affinity to cIAP1 in human MDA-MB-231 cells assessed as induction of protein degradation after 1 hr by ELISA Binding affinity to cIAP1 in human MDA-MB-231 cells assessed as induction of protein degradation after 1 hr by ELISA	[PMID: 24320998]
MDA-MB-231	GI₅₀	<0.06 nM Compound: 14, AZD5582	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by Alamar Blue assay Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by Alamar Blue assay	[PMID: 24320998]

In Vitro

AZD5582 (20 nM; 48 hours) inhibits cell viability by cooperation with IFNγ or viral double-stranded RNA (dsRNA) in H1975 NSCLC cells^[2].
AZD5582 (20 nM; 17 or 25 hours) downregulates cIAP-1, activates RIPK1 (upstream regulator of caspase-8), and triggers the activation of extrinsic (caspase-8) and intrinsic (caspase-9) apoptosis pathways, causing the cleavage of caspase-3 and caspase-7^[2].
AZD5582 (20 nM; 48 hours) involves in apoptosis due to induction of cell death and active caspase-3/8 activities by AZD5582 and IFNγ co-treatment in HCC827 NSCLC cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

H1975 NSCLC cell line
Concentration:

20 nM
Incubation Time:

48 hours
Result:

Cooperated with IFNγ or viral double-stranded RNA (dsRNA) to inhibit cell viability even cell death.

Apoptosis Analysis^[2]

Cell Line:

HCC827 NSCLC cell line
Concentration:

20 nM
Incubation Time:

48 hours
Result:

Had an inhibitory effect on cell viability by cooperating with IFNγ.

Western Blot Analysis^[2]

Cell Line:

H1975 NSCLC cell line
Concentration:

20 nM
Incubation Time:

17 or 25 hours
Result:

Down-regulated cIAP-1, activated RIPK1 (upstream regulator of caspase-8), triggered the cleavage (activation) of caspase-3,7,8 and 9.

In Vivo

AZD5582 (intravenous injection; 0.1-3.0 mg/kg; once a week; 2 weeks) causes degradation of cIAP1 and caspase 3 cleavage in tumor cells, and after a two-week treatment, the tumors largely resolved; when the mice are given a medium dose (0.5 mg/kg) of AZD5582, cIAP1 degrades after administration, but it takes a while time to reach apoptosis-inducing effect^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

MDA-MB-231 xenograft-bearing mice^[1]
Dosage:

0.1 mg/kg, 0.5 mg/kg, 3.0 mg/kg
Administration:

Intravenous injection; once a week; 2 weeks
Result:

Resulted in cIAP1 degradation and caspase-3 cleavage within tumor cells and causes substantial tumor regressions following two weekly doses of 3.0 mg/kg

Chemical Information

CAS. Nr. 1258392-53-8
Appearance Solid
Molecular Weight 1015.29
Formel C₅₈H₇₈N₈O₈
Color White to yellow
SMILES

CN[C@@H](C)C(N[C@H](C(N1[C@H](C(N[C@H]2C3=CC=CC=C3C[C@H]2OCC#CC#CCO[C@H]4[C@@H](NC([C@@H]5CCCN5C([C@@H](NC([C@H](C)NC)=O)C6CCCCC6)=O)=O)C(C=CC=C7)=C7C4)=O)CCC1)=O)C8CCCCC8)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Publications (16)

All Cell Proliferation/Viability AssayCell Imaging/StainingFlow CytometryWBIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

TSC22 domain family member 3 links natural killer cells to CD8+ T cell-mediated drug hypersensitivity. [Abstract]

2025 Jun 21;10(1):196. PMID: 40544157
Antioxidants (Basel)

Potential Phytotherapy of DSS-Induced Colitis: Ameliorating Reactive Oxygen Species-Mediated Necroptosis and Gut Dysbiosis with a New Crataegus pinnatifida Bunge Variety-Daehong. [Abstract]

2024 Mar 12;13(3):340. PMID: 38539873
Cancer Immunol Res

Inhibitor of apoptosis proteins (IAP) antagonist induces T-cell proliferation after cross-presentation by dendritic cells. [Abstract]

2023 Apr 3;11(4):450-465. PMID: 36753604

AZD5582 purchased from MedChemExpress. Usage Cited in: Cancer Immunol Res. 2023 Apr 3;11(4):450-465. [Abstract]

AZD5582 (0.1-1 μM; 24 h) decreases the expression of cIAP1, cIAP2 and XIAP in GM-CSF DCs.
Biomater Adv

Optimized lipopolymers with curcumin to enhance AZD5582 and GDC0152 activity and downregulate inhibitors of apoptosis proteins in glioblastoma multiforme. [Abstract]

2023 Nov:154:213639. PMID: 37793310
Biomater Adv

Enhanced activity of AZD5582 and SM-164 in rabies virus glycoprotein-lactoferrin-liposomes to downregulate inhibitors of apoptosis proteins in glioblastoma. [Abstract]

2022 Feb:133:112615. PMID: 35525732
J Mol Med (Berl)

EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma. [Abstract]

2022 Apr;100(4):629-643. PMID: 35247069

AZD5582 purchased from MedChemExpress. Usage Cited in: J Mol Med (Berl). 2022 Apr;100(4):629-643. [Abstract]

Evaluation of cell growth inhibition by AZD5582 on a panel of 6 cell lines including 5 cancer lines (Huh7, M231, H727, HepG2, and A549) and 1 normal line (MSC). Cells were treated by AZD5582 at indicated series of concentration for 24 h and then analyzed for cell viability and proliferation by CCK-8 kit.

AZD5582 purchased from MedChemExpress. Usage Cited in: J Mol Med (Berl). 2022 Apr;100(4):629-643. [Abstract]

AZD5582 (20 nM). Detection of FITC-phalloidin (green) labeled filamentous actin (F-actin) cytoskeleton in Huh7 cells.

AZD5582 purchased from MedChemExpress. Usage Cited in: J Mol Med (Berl). 2022 Apr;100(4):629-643. [Abstract]

AZD5582 (20 nM). The expression levels of activated caspase-8 (C-Casp-8), -9 (C-Casp-9), and -3 (C-Casp-3) in Huh7 cells were compared using flow cytometry with a specific FITC-labeled inhibitor.

AZD5582 purchased from MedChemExpress. Usage Cited in: J Mol Med (Berl). 2022 Apr;100(4):629-643. [Abstract]

Cells were treated with vector (Ctrl), 2.0 ng/mL EV-T TRAIL (EV-T) and/or 20 nM AZD5582 (AZD)/(Combi) for 24 hours, respectively, followed by Western blotting analysis using antibodies against cFLIP, BC1-2, MCl-1, Survivin, cIAP-1, XIAP, and GAPDH. Huh7 cells were treated and analyzed.

AZD5582 purchased from MedChemExpress. Usage Cited in: J Mol Med (Berl). 2022 Apr;100(4):629-643. [Abstract]

Tumor growth/volume curves. Each treatment comprises of intratumoral injection per animal of 100 μL saline vehicle (Ctrl), 8.0 ng EV-T TRAIL (EV-T), 2.0 μg AZD5582 (AZD), or the combination of AZD and EV-T (Combi), respectively, and total three injections were performed with a 48-h interval.
Biochim Biophys Acta Mol Basis Dis

Directed elimination of senescent cells attenuates development of osteoarthritis by inhibition of c-IAP and XIAP. [Abstract]

2019 Oct 1;1865(10):2618-2632. PMID: 31251987
Cell Signal

Smac mimetic promotes TNF-α to induce apoptosis of gallbladder carcinoma cells. [Abstract]

2020 Aug:72:109654. PMID: 32334028
Acta Histochem

Exosomal delivery of AZD5582 to overcome TRAIL resistance as an optimal therapy against triple-negative breast cancer. [Abstract]

2025 May 24;127(3):152270. PMID: 40413911
bioRxiv

2026 Feb 6.
Res Sq

2026 Jan 13.
Icahn School of Medicine at Mount Sinai

2025.
University of Cologne

2024.
bioRxiv

Integrator complex subunit 12 knockout overcomes a transcriptional block to HIV latency reversal. [Abstract]

2024 Sep 3:2024.08.30.610517. PMID: 39257755
bioRxiv

A CRISPR screen of HIV dependency factors reveals CCNT1 is non-essential in T cells but required for HIV-1 reactivation from latency. [Abstract]

2023 Jul 28:2023.07.28.551016. PMID: 37546973
Research Square Preprint

2021 May.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (98.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.9849 mL

4.9247 mL

9.8494 mL

5 mM

0.1970 mL

0.9849 mL

1.9699 mL

10 mM

0.0985 mL

0.4925 mL

0.9849 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 50 mg/mL (49.25 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hennessy EJ, et al. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919. [Content Brief]

[2]. Qin Hao, et al. IF-γ and Smac mimetics synergize to induce apoptosis of lung cancer cells in a TNFα-independent manner,Cancer Cell Int. 2018; 18: 84. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.9849 mL	4.9247 mL	9.8494 mL	24.6235 mL
	5 mM	0.1970 mL	0.9849 mL	1.9699 mL	4.9247 mL
	10 mM	0.0985 mL	0.4925 mL	0.9849 mL	2.4624 mL
	15 mM	0.0657 mL	0.3283 mL	0.6566 mL	1.6416 mL
	20 mM	0.0492 mL	0.2462 mL	0.4925 mL	1.2312 mL
	25 mM	0.0394 mL	0.1970 mL	0.3940 mL	0.9849 mL
	30 mM	0.0328 mL	0.1642 mL	0.3283 mL	0.8208 mL
	40 mM	0.0246 mL	0.1231 mL	0.2462 mL	0.6156 mL
	50 mM	0.0197 mL	0.0985 mL	0.1970 mL	0.4925 mL
	60 mM	0.0164 mL	0.0821 mL	0.1642 mL	0.4104 mL
	80 mM	0.0123 mL	0.0616 mL	0.1231 mL	0.3078 mL

Bioz

Keywords

AZD5582

16 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

AZD5582

Birinapant

GDC-0152

SM-164

Tolinapant

LCL161

Xevinapant

BV6

CUDC-427

Z-VAD-FMK

Phorbol 12-myristate 13-acetate

Xevinapant hydrochloride

Vorinostat

Publications Citing Use of MedChemExpress (MCE) AZD5582

Alle IAP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (16)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

AZD5582

Birinapant

GDC-0152

SM-164

Tolinapant

LCL161

Xevinapant

BV6

CUDC-427

Z-VAD-FMK

Phorbol 12-myristate 13-acetate

Xevinapant hydrochloride

Vorinostat

Publications Citing Use of MedChemExpress (MCE) AZD5582

Alle IAP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (16)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AZD5582 Related Classifications

HY-12600 Related Classifications

Bioz